Condition (MeSH)
Smallpox
ClinicalTrials.gov lists 71 trials for Smallpox or a narrower condition beneath it. National Institute of Allergy and Infectious Diseases (NIAID) has the most among industry and government lead sponsors, with 19.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase (log scale)
1 more section with rows
71 of the 71 trials are tagged with Smallpox itself; the rest are tagged with a narrower condition beneath it.
When did Smallpox trials start? (20)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 1 trial is registered to start in 2027 or later, and not listed here.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 2/3
- Phase 3
- Phase 4
- Not applicable
- Observational
Top of scale: 7
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 1 |
| 2025 | 3 |
| 2023 | 2 |
| 2022 | 3 |
| 2021 | 1 |
| 2020 | 2 |
| 2019 | 3 |
| 2015 | 1 |
| 2014 | 1 |
| 2013 | 3 |
Showing 10 of 20 earlier years.
No forecast is made for this condition: it averages 2.0 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 3 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Smallpox trials in? (9)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 19 |
| Phase 1/2 | 6 |
| Phase 2 | 23 |
| Phase 2/3 | 2 |
| Phase 3 | 9 |
| Phase 4 | 2 |
| Not applicable | 1 |
| Observational | 8 |
| Expanded access | 1 |
How many Smallpox trials are recruiting? (9)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 1 |
| Recruiting | 2 |
| Enrolling by invitation | 1 |
| Active, not recruiting | 3 |
| Available | 1 |
Showing 5 of 9 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Smallpox trials? (13)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| National Institute of Allergy and Infectious Diseases (NIAID) | 19 |
| Bavarian Nordic | 11 |
| SIGA Technologies | 8 |
| Emergent BioSolutions | 7 |
| Sanofi Pasteur, a Sanofi Company | 5 |
Showing 5 of 13 sponsors.
Which drugs are being tested for Smallpox? (4)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| IMVAMUNE | 10 |
| Tecovirimat | 4 |
| TPOXX | 3 |
| Brincidofovir | 2 |
Interventions as named in the registry (11)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| MVA Smallpox Vaccine | 8 |
| Live vaccinia virus vaccine | 4 |
| smallpox vaccine CJ-50300 | 3 |
| MVA-BN standard regimen | 2 |
| Dryvax | 2 |
Showing 5 of 11 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Smallpox trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Diarrhoea | 28 | 1 |
| Respiratory failure | 24 | 1 |
| Acute graft versus host disease | 22 | 1 |
| Pyrexia | 22 | 1 |
| Multi-organ failure | 17 | 1 |
Showing 5 of 10 adverse events.
Which publications cover Smallpox? (41)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| One- and Two-Dose Vaccinations With Modified Vaccinia Ankara-Bavarian Nordic Induce Durable B-Cell Memory Responses Comparable to Replicating Smallpox Vaccines. | The Journal of infectious diseases | 2023 | Yes |
| Clinical Activity of Olvimulogene Nanivacirepvec-Primed Immunochemotherapy in Heavily Pretreated Patients With Platinum-Resistant or Platinum-Refractory Ovarian Cancer: The Nonrandomized Phase 2 VIRO-15 Clinical Trial. | JAMA oncology | 2023 | Yes |
| Possible Mpox Protection from Smallpox Vaccine-Generated Antibodies among Older Adults. | Emerging infectious diseases | 2023 | Yes |
| Monkeypox (mpox) virus: Classification, origin, transmission, genome organization, antiviral drugs, and molecular diagnosis. | Journal of infection and public health | 2023 | Yes |
| Complement-dependent mpox-virus-neutralizing antibodies in infected and vaccinated individuals. | Cell host & microbe | 2023 | Yes |
Showing 5 of 41 publications.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence, rare-disease identity, and sub-conditions in mesh.